When was Bluebird Bio founded?

Bluebird Bio was founded in 1992 and raised its 1st funding round 12 years after it was founded.

Where is Bluebird Bio located?

Bluebird Bio is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts.

How many employees does Bluebird Bio have?

As of Mar 31, 2026, the latest employee count at Bluebird Bio is 331.

Is Bluebird Bio a funded company?

Bluebird Bio is a funded company, having raised a total of $136M across 9 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Oct 04, 2004.

How much is Bluebird Bio worth?

The last known valuation of Bluebird Bio was $***** as of Feb 21, 2025.

When was the latest funding round of Bluebird Bio?

Bluebird Bio's latest funding was a $***** Post IPO round on Jun 03, 2022, with participation from 1 investor.

What is the annual revenue of Bluebird Bio?

Annual revenue of Bluebird Bio is $83.8M as on Dec 31, 2024.

Where does Bluebird Bio rank among its competitors?

Bluebird Bio ranks 33rd amongst 3799 active competitors, of which 1292 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Human Longevity, which secured $39.8M in Aug, 2024.

Who are the top competitors of Bluebird Bio?

Bluebird Bio's top competitors include Jazz Pharmaceuticals, Alnylam and BridgeBio. Among them, Human Longevity secured the most recent funding round in August, 2024.

Bluebird Bio - 2026 Company Profile, Funding, Competitors & Financials

Bluebird Bio is an acquired company based in Cambridge (United States), founded in 1992. It operates as a Developer of gene therapies for severe genetic and rare diseases. Bluebird Bio has raised $136M in funding from investors like TVM Capital, Third Rock Ventures and Easton Capital Investment Group, with last known valuation of $*****. The company has 3799 active competitors, including 1292 funded and 914 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Alnylam and BridgeBio.

Company Details

Developer of gene therapies for severe genetic and rare diseases. The company's products include Lenti-D for Childhood Cerebral Adrenoleukodystrophy (ALD) and LentiGlobin for rare hemoglobinopathies. The company's other products for multiple myeloma and HPV-associated cancer are in the preclinical stage. The company is also using homing endonuclease and megaTAL gene-editing technologies in a variety of potential applications and disease areas, including hematology and oncology.

Website: bluebirdbio.com
Social
Registered Address: Cambridge, Massachusetts

Key Metrics

Founded Year

1992

Location

Cambridge, United States

Stage

Acquired

Total Funding

$136M in 9 rounds

Latest Funding Round

Post IPO, Jun 03, 2022, $*****

Last Known Valuation

$***** as on Feb 21, 2025

Investors

TVM Capital & 10 more

Ranked

33^rd among 3799 active competitors

Annual Revenue

$83.8M as on Dec 31, 2024

Employee Count

331 as on Mar 31, 2026

Investment & Acquisitions

Pregenen & 1 more

Similar Companies

Jazz Pharmaceuticals & 3774 more

Exit Details

Acquired by The Carlyle Group (Feb 21, 2025)

View Bluebird Bio's full profile

Bluebird Bio is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Bluebird Bio, Inc. CIN: 786164 , United States, Active	Apr 25, 2024	-	-	-
Bluebird Bio, Inc. CIN: 133680878 , United States, Active	Dec 26, 999	$83.8M (As on Dec 31, 2024)	272 (As on Dec 31, 2024)	-

Bluebird Bio got acquired by The Carlyle Group and SK Capital on Feb 21, 2025 at an acquisition amount of $29M. It was facilitated by Leerink Partners, Latham & Watkins, Bourne Partners and 3 more.

Click here to take a look at Bluebird Bio's acquisition in detail

Bluebird Bio has raised a total funding of $136M over 9 rounds. Its first funding round was on Oct 04, 2004. Its latest funding round was a Post IPO round on Jun 03, 2022 for $*****. 1 investor participated in its latest round. Bluebird Bio has 11 institutional investors.

Here is the list of recent funding rounds of Bluebird Bio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 03, 2022	6230546	Post IPO	9319486	7831715	1945928	8806497
Sep 08, 2021	4656844	Post IPO	6392048	4194589	5689887	9795682
Oct 27, 2012	8188962	Grant (prize money)	9983410	8250152	5460547	2378220

Access funding benchmarks and valuations. Sign up today!

View details of Bluebird Bio's funding rounds and investors

Bluebird Bio's employee count trend

Bluebird Bio has 331 employees as of Mar 26. Here is Bluebird Bio's employee count trend over the years:

Uncover Bluebird Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Bluebird Bio include Jazz Pharmaceuticals, Alnylam and BridgeBio. Here is the list of Top 10 competitors of Bluebird Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Prospect Venture Partners, Versant Ventures ... & 14 others	82/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, BB Biotech & 13 others	79/100
3rd	BridgeBio 2015, Palo Alto (United States), Acquired	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	79/100
4th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Invesco, Allen & Company & 9 others	79/100
5th	Human Longevity 2013, San Diego (United States), Series B	Provider of precision medicine, preventative health assessments, and longevity care	$409M	Celgene, General Electric & 20 others	76/100
6th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	76/100
7th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Omega Funds, Bezos Expeditions & 17 others	75/100
8th	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, BB Biotech & 10 others	75/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
10th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	Omega Funds, BB Biotech & 14 others	74/100
33rd	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	RA Capital Management, Sanofi Ventures & 9 others	70/100